VUDALIMAB

Approval Year

Substance Class	Protein Created by `admin` on `Sat Dec 16 14:30:03 GMT 2023` Edited by `admin` on `Sat Dec 16 14:30:03 GMT 2023`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1
Sequence Origin	HUMANIZED
Sequence Type	COMPLETE
Record UNII	4I9I5X3Z6N
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VUDALIMAB

Official Name

English

IMMUNOGLOBULIN HALF-IG G1-KAPPA/SCFV-H-CH2-CH3, ANTI-(HOMO SAPIENS CTLA4 (CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4, CD152)) AND ANTI-(HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1, CD279)), MONOCLONAL ANTIBODY, BISPECIFIC

Common Name

English

Vudalimab [WHO-DD]

Common Name

English

PD-1 X CTLA-4 DUAL CHECKPOINT INHIBITOR XMAB20717

Common Name

English

IMMUNOGLOBULIN, ANTI-(HUMAN CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN 4) (HUMAN-MUS MUSCULUS MONOCLONAL XMAB20717 SINGLE-CHAIN VARIABLE FRAGMENT VL-LINKER-VH) FUSION PROTEIN WITH IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN C-REGION C-TERMINAL FRAGMENT), (260

Common Name

English

ANTI-PD-1/ANTI-CTLA-4 XMAB20717

Common Name

English

XMAB20717

Code

English

VUDALIMAB [USAN]

Common Name

English

vudalimab [INN]

Common Name

English

ANTI-PD1/CTLA4 BISPECIFIC ANTIBODY XMAB20717

Common Name

English

XMAB-20717

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C150463